Hamburg

• EORTC-1407-GUCG: A randomized phase III trial comparing conventional-dose chemotherapy using paclitaxel, ifosfamide, and cisplatin (TIP) wit … Ended recruitment
  2024-513509-30-00 5 2016-01-11 Progressive or recurrent germ cell tumor (measurable or non-measurable
• Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lun … Ended recruitment
  2023-505981-26-00 5 2015-11-20 Non−Small Cell Lung Cancer
• PALLAS - PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy vers … Ended recruitment
  2024-514841-12-00 5 2015-10-27 To determine whether the addition of palbociclib to adjuvant endocrine
• Ruxolitinib versus Best Available Therapy in patients with high-risk polycythemia vera or high-risk essential thrombocythemia – The Ruxo-BEA … Ended recruitment
  2024-515619-23-00 4 2015-06-29 essential thrombocythemia
• An Efficacy and Safety Study of JNJ56021927 in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC) Ended recruitment
  2023-508606-26-00 5 2015-04-23 Metastatic castration-resistant prostate cancer (mCRPC)
• Further 2 years of adjuvant imatinib may improve recurrence-free survival (RFS) of patients who are at a high risk of GIST recurrence despit … Ended recruitment
  2024-512243-23-00 5 2014-11-07 gastrointestinal stromal tumor
• Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2negative primary breast cancer. Ended recruitment
  2024-511096-15-00 5 2014-08-01 Breast Cancer
• Phase 2a study to assess the efficacy and safety of GIA632 in adult participants with moderate to severe atopic dermatitis Halted
  2025-521503-43-00 4 2026-02-12 Atopic dermatitis
• A prospective, randomised, multi-centre, double-blind, placebo-controlled Phase III trial to investigate the efficacy and safety of lozenges … Halted
  2025-521764-35-01 5 2026-01-27 acute pharyngitis
• A prospective, multicentre, randomised, double-dummy, double-blind, placebo-controlled 3-way Phase III study to investigate the efficacy and … Halted
  2022-502903-31-00 5 2025-11-05 Patients with ADHD (according to ICD-10 / DSM-5)
• NeoART – A phase Ib/II platform trial evaluating the safety and activity of neoadjuvant trastuzumab-deruxtecan containing combination therap … Halted
  2024-518841-12-00 9 2025-03-25 HER2 positive resectable esophagogastric adenocarcinoma
• A Phase 1b Study of Neoadjuvant Xaluritamig in Subjects With Newly Diagnosed Localized Intermediate or High-Risk Prostate Cancer Halted
  2024-511965-13-00 3 2024-11-25 Newly diagnosed localized Intermediate or High‐Risk Prostate Cancer
• A trial to understand if AZD0486 is safe and helps in people with Relapsed or Refractory B-cell acute lymphoblastic leukemia (B-ALL) Halted
  2023-505840-20-00 9 2024-08-16 B-Cell Acute Lymphoblastic Leukaemia
• A global study of volrustomig (MEDI5752) plus chemotherapy versus pembrolizumab plus chemotherapy for participants with metastatic non-small … Halted
  2023-503298-39-00 5 2024-06-13 Metastatic Non-Small Cell Lung Cancer (mNSCLC)
• A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulator … Halted
  2024-512626-28-00 5 2024-03-28 Duchenne Muscular Dystrophy
• A randomized, open-label, multicentric, two-arm pivotal trial of SonoCloud-9 combined with carboplatin (CBDCA) vs standard of care lomustine … Halted
  2023-505829-14-00 5 2023-12-22 First recurrence glioblastoma
• To Investigate whether the combination of molidustat and an IDH1 inhibitor (ivosidenib) effectively inhibits leukaemia cells in patients wit … Halted
  2024-514051-15-00 7 2023-07-10 Adult patients with relapsed or refractory IDH1-mutated AML or relapse
• Study of efficacy and safety of JDQ443 single-agent as first-line treatment for patients with locally advanced or metastatic KRAS G12C- muta … Halted
  2024-511708-18-00 4 2022-12-06 Locally advanced or metastatic KRAS G12C-mutated non-small cell lung c
• Study of Avelumab in combination with Lenvatinib for children with primary CNS tumors Halted
  2024-512940-51-00 3 2021-11-24 Central Nervous System Tumors
• Assessment of the safety and effects on the body of investigational products when used on psoriatic skin Ended
  2025-522446-51-00 3 2025-10-17 Plaque psoriasis
• Investigation of 3 different doses of a newly developed vaginal ring releasing estriol for the treatment of vaginal atrophy - a placebo-cont … Ended
  2024-514302-31-00 4 2025-07-16 Vaginal atrophy
• A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of … Ended
  2024-517814-13-00 4 2025-04-30 Moderate to Severe Atopic Dermatitis
• Axicabtagene Ciloleucel CAR T-Cells in Patients with relapsed or refractory primary mediastinal B-Cell Lymphoma Ended
  2024-510972-19-00 4 2025-03-13 Primary mediastinal large B-cell lymphoma (PMBCL)
• Phase 1/2 Study of Cobolimab plus Dostarlimab in Pediatric and Young Adult Participants with Newly Diagnosed and Relapsed/Refractory Tumors Ended
  2024-511350-41-00 9 2025-03-13 Relapsed/Refractory Tumors

Showing 817–840 of 1,087 trials